GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptamer Group PLC (LSE:APTA) » Definitions » NonCurrent Deferred Liabilities

Aptamer Group (LSE:APTA) NonCurrent Deferred Liabilities : £0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Aptamer Group NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Aptamer Group's non-current deferred liabilities for the quarter that ended in Dec. 2023 was £0.00 Mil.

Aptamer Group NonCurrent Deferred Liabilities Historical Data

The historical data trend for Aptamer Group's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptamer Group NonCurrent Deferred Liabilities Chart

Aptamer Group Annual Data
Trend Mar19 Mar20 Jun22 Jun23
NonCurrent Deferred Liabilities
- - - -

Aptamer Group Semi-Annual Data
Mar19 Mar20 Dec21 Jun22 Dec22 Jun23 Dec23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial - - - - -

Aptamer Group NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Aptamer Group's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptamer Group (LSE:APTA) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Innovation Way, Windmill House, York, GBR, YO10 5BR
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics.

Aptamer Group (LSE:APTA) Headlines

No Headlines